Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Public offering nets $29.7mm for Mustang Bio

Executive Summary

Mustang Bio Inc. netted $29.7mm through a public offering of 7.9mm common shares (including the overallotment) at $4. The gene/cell therapy firm also recently received $15mm in a venture debt financing signed last month with Horizon Technology; the agreement totals $20mm, and Mustang can draw down the remaining $5mm pending achievement of certain milestones.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies